Fogorvosi szemle, 2006 (99. évfolyam, 1-6. szám)

2006-06-01 / 3. szám

FOGORVOSI SZEMLE 99. évf. 3. sz. 2006. 105 részletezése értelemszerűen e közleménynek nem lehet feladata. Fogorvosi szempontból viszont említést érde­melnek bizonyos szájsebészeti rekonstrukciós műtétek, amelyek az ilyen súlyos állapotban lévő betegek életmi­nőségét komplex módon javíthatják, és segítségükkel a sialorrhoea-t okozó panaszok is enyhíthetők vagy meg­szűntethetek [111, 141, 143]. Irodalom 1. Akiniwa K: Re-examination of acute toxicity of fluoride. Fluoride 1997; 30:89-104. 2. Allen T: Suspected esophageal foreign body. Choosing appropiate management. JACEP1979; 8:101-105. 3. Asher RS, Winquist H: Applience therapy for chronic drooling in patients with mental retardation. Spec Care Dentist 1994; 14: 30-32. 4. Askar I, Gurlek A, Sevin K: Lateral facial cleft. Plastic Surg2001; 47: 355-356. 5. Ball JV, Horrocks EN: Partial glossectomy for the treatment of an anterior open bite. A case report. Br J Orthodontics 1995; 22: 185-189. 6. Bardon T, Ruckebusch M: Changes in 5-HIAA and 5-HT levels in lumbar CSF following morphine administration to conscious dogs. Neurosci Lett 1984; 49:147-151. 7. Bartolocci AA: Estimation and comparison of proportions. In: Buyse ME, Staquet MJ, Silvester RJ (eds.): Cancer Clinical Trials. Oxford University Press, Oxford, 1990; 337-360. 8. Bax M: Editorial. Drooling. Dev Med Child Neurol 1992; 34:847-848. 9. Benedek-Spät E, Székely T: Long-term follow-up of the effect of tympanic neurectomy on sialadenosis and recurrent parotitis. Acta Otolaryngol 1985; 100:437-443. 10. BhatiaKP, Mlinchau A, Brown P: Botulinumtoxin is a useful treat­ment in excessive drooling of saliva. J Neurol Neurosurg Psychiatry 1999; 67: 697. 11. Bhidayasiri R, Truong DD: Expanding use of botulinum toxin. J Neurol Sei 2005; 235: 1-9. 12. Bigalke H: Botulinum toxine: Wirksamkeit und Antigenität. Klin Neurophysiol2001 ; 32: 210-213. 13. Blasco AP, Allare JH, Consortium On Drooling: Drooling in the developmental^ disabled: Management practices and recommen­dations. Dev Med Child Neurol 1992; 34: 849-862. 14. Blasco PA, Stansburry JC: Glycopyrrolate treatment of chronic drooling. Arch Pediatr Adolesc Med 1996; 150: 932-935. 15. Borg M, Hirst F: The role of radiation therapy in the management of sialorrhoea. Int J Radiat Oncol Biol Phys 1998; 41:1113-1119. 16. Boyce HW, Bakheet MR: Sialorrhoea: A review of a wexing, often unrecognized sign of oropharyngeal and esophageal disease. J Clin Gastroenterol2005; 39: 89-97. 17. Boyd EM: The acute oral toxicity of phenacetin. Toxicol Appl Phar­­maco/1959; 1:240-249. 18. Bradly FB: Dementia with Lewy bodies. Continuum: Lifelong learn­ing in Neurology. Dementia 2004; 10: 81-112. 19. Bruhwyler J, Liégeois JF, Bergman J, Carey G, Goudie A, Tay­lor A et al.: JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: a review of its behavioural properties. Pharmacol Res 1997; 36: 23-33. 20. Brundage SR, Moore WD: Submandibular gland resection and bilateral parotid duct ligation as a management for chronic drooling in cerebral palsy. Plastic Reconst Surg 1989; 83: 443-446. 21. Bushara KO: Sialorrhoea in amyotrophic lateral sclerosis: a hypoth­esis of a new treatment - botulinum toxin A injections of the parotid glands. Med Hypothesis 1997; 48: 337-339. 22. Camp-Bruno JA, Winsberg BG, Geen-Parsons AR, Abrams JP: Efficacy of benztropine therapy for drooling. Dev Med Child Neurol 1989;31:309-319. 23. Cavanaugh K, ParkA: Postparotidectomy fistula: a different treat­ment for an old problem. Int J Pediat Otorhinolaryngol 1999; 47: 265-268. J 24. Chang CJ, Wong AMK: Intraductal laser photocoagulation of the [ bilateral parotid ducts for reduction of drooling in patients with cerebral palsy. Plastic Reconst Surg 2001; 107: 907-913. I 25. Cheng AS: Control of oral secretions in bulbar amyotrophic lateral sclerosis using botulinum toxin type A: A pilot study and safety trial. Arch Phys Med Rehab//2003; 84: Abs. 165, A33. 26. De Conno F, Sbanotto A, Ripamonti C, Ventafridda V: Mouth care. In: Doyle D, Hanks G, Cherny N, Calman K (eds.): Oxford Textbook of Palliative Medicine. 3rd ed. Oxford University Press, New York, 2004; 673-687. 27. Corrigan FM, McDonald S, Reynolds GP: Clozapine-induced hypersalivation and the alpha 2 adrenoreceptor (letter). BrJ Psy­chiatry 1995; 167: 412. 28. Craddock HL, Nattress BR, Scupham SC: The use of a removable appliance to improve oral continence in an elderly dentate patient. Eur J Prosthodont Restor Dent 2004; 12: 29-32. 29. Crysdale WS, White A: Submandibular duct relocation for drool­ing: a 10-year experience. Otolaryngol Head Neck Surg 1989; 101: 87-92. 30. Crysdale WS: Drooling: experience with team assessment and management. Clin Ped/afr1992; 31: 77-80. 31. DastgeerGM, Mikolich DJ: Drooling caused by a swallowed den­ture plate. Ann Emer Med 1985; 14:1245. 32. Davydov L, Botts SR: Clozapine-induced hypersalivation. Ann Pharmacother2000; 34: 662-665. 33. Doherty MJ: The quicksilver prize: Mercury poisoning aboard HMS Triumph and HMS Phipps. Neurology 2004; 62: 963-966. 34. Domarcki LS, Sisson LA: Decreasing drooling with oral motor stimulation in children with multiple disabilities. Am J Occup Ther 1990; 44: 680-684. 35. Eadie MJ, Tyrer JH: Alimentary disorder in parkinsonism. Austr Ann Med 1965; 14: 13-22. 36. Edwards LL, Quigley EM, Pfeiffer RF: Gastrointestinal dysfunc­tion in Parkinson’s disease: frequency and pathophysiology. Neuro­logy 1992; 42: 726-732. 37. Ekedahl C: Surgical treatment of drooling. Acta Otolaryngol 1974; 77:215-220. 38. Ellies M, Laskawi R, Rohrbach-Vollard S, Arglebe C, Beuche W: Botulinum toxin to reduce salivary flow: selected indications for ultra­sound-guided toxin application into salivary glands. Laryngoscope 2002; 112: 82-86. 39. Ellies M, Laskawi R, Rohrbach-Vollard S, Arglebe C: Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies. J Oral Maxillofac Surg 2003; 61: 454-457. 40. Ethunandan M, McPherson DW: Persistant drooling: treatment by bilateral submandibular duct transposition and simultaneous sublin­gual gland excision. Ann R Coll Surg Eng 1998; 80: 279-282. 41. Fear DW, Hitchcock RP, Fonseca RJ: Treatment of chronic drool­ing: A preliminary report. Oral Surg Oral Med Oral Pathol 1988; 66: 163-166. 42. Filippi S, Monaco P, Godano U, Calbucci F: Sialorrhoea from fourth ventricle hydrocephalus. Case report. J Neurosurgery 1994; 81:297-298. 43. Finklestein DM, Crysdale WS: Evaluation and management of the dooling patient. J Otolaryngol 1992; 21: 414-418. 44. Fitton A, Heel RC: Clozapine: a review of its pharmacological properties, and therapeutic use in schizophrenia: Drugs 1990; 40: 722-747. 45. Frederick FJ, Stewart IF: Effectiveness of transtympanic neu­rectomy in management of sialorrhoea occuring in mentally retarded patients. J Otolaryngol 1982; 11: 289-292. 46. Freeman JJ, Altieri RH, Babtiste HJ, KuoT, Crittenden S, Fogarty K et al. : Evaluation and management of sialorrhoea in pregnancy with concommitant hyperemesis. J Natl Med Assoc 1994; 86: 704-708. 47. Freundreich O: Druq-induced sialorrhoea. Drugs Today 2005; 41:411-418. 48. Friedman A, PotulskaA: Quantitative assessment of parkinsonian sialorrhoea and results of treatment with botulinum toxin. Parkinso­nism Ret Dis 2001 ; 7: 329-332.

Next

/
  • Layout
  • Zoom
  • Rotation
Thumbnails
Contents